Emergent BioSolutions (EBS) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Turn Therapeutics (TTRX) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 72.9% versus a loss of 28.7%. Turn Therapeutics is the larger company by market cap ($367.4 million vs $362.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EBS | TTRX |
|---|---|---|
| Share price | $7.07 | $12.10 |
| Market cap | $362.50M | $367.45M |
| 1-day change | +1.73% | +3.95% |
| YTD return | -42.80% | +207.11% |
| 1-year return | -28.73% | +72.86% |
| 5-year return | -86.05% | — |
| Forward P/E | 6.76 | — |
| EPS (TTM) | $-3.46 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.06 | $26.50 |
| 52-week low | $4.36 | $2.57 |
| Distance from 52-week high | -49.72% | -54.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +55.59% | +106.61% |
| Average volume | 1.16M | 114.62K |
| Shares outstanding | 51.27M | 30.37M |
| Employees | 900 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TTRX has outperformed EBS by 101.6 percentage points over the past year.
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Healthcare · Drug Manufacturers - Specialty & Generic · 900 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Healthcare · Biotechnology · 2 employees
EBS vs TTRX FAQ
Which is bigger, Emergent BioSolutions or Turn Therapeutics?
Turn Therapeutics (TTRX) is larger, with a market capitalization of $367.45M compared with $362.50M for Emergent BioSolutions (EBS).
Which stock has performed better over the past year, EBS or TTRX?
TTRX returned +72.86% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Emergent BioSolutions and Turn Therapeutics in the same industry?
Both are in the Healthcare sector, but in different industries: Drug Manufacturers - Specialty & Generic for Emergent BioSolutions and Biotechnology for Turn Therapeutics.